Treatment outcome analysis of chemotherapy combined with modulated electro-hyperthermia compared with chemotherapy alone for recurrent cervical cancer, following irradiation

Treatment characteristics

Treatment characteristics

CONTACT US

Summary

A combinational therapy of chemotherapy and hyperthermia is set to determine its effectiveness with patients with recurrent6 cervical cancer. It has been demonstrated to improve the response rate. the overall response rate for patients treated with chemotherapy combined with modulated electro-hyperthermia was significantly greater than that for those treated with chemotherapy alone.

Patients characteristics

Patients had histologically confirmed cervical cancer (histological diagnosis of squamous cell carcinoma or adenocarcinoma). A total of 20 subjects were included in the chemo- therapy only group, and 18 subjects were included in the chemotherapy combined with modulated electro-hyperthermia group.

Methodology

Chemotherapy

All patients received platinum-based chemotherapy for recurrence. The goal of combined chemotherapy with modulated electro-hyperthermia was to administer 36 sessions of modulated electro-hyperthermia during chemotherapy. All patients were evaluated for toxicity each week.

Modulated electro-hyperthermia

Modulated electro-hyperthermia treatment was applied using an EHY2000 clinical heating device (Oncotherm GmbH) set at a 13.56 MHz carrier frequency, and the amplitude was modulated according to a time fractal pattern. Modulated electro-hyperthermia was performed for 60 min. The patients were placed in a supine position on a water mattress electrode. A circular upper electrode (30 cm in diameter) was coupled over the recurrent cervical mass or PAN mass.
The power output was 80 W for the first 10 minutes, 120 W for the next 10 min and 150 W for the remaining treatment time.

Treatment

For patients diagnosed with cervical cancer, the time to relapse following curative treatment was 8.95 months following the first treatment for the chemotherapy only group and 9.16 months for the combined chemotherapy with modulated electro-hyperthermia group. The overall response rate (CR+PR+SD/PD) to treatment was significantly greater in the group that underwent chemotherapy combined with modulated electro-hyperthermia.
In chemotherapy only group (n=20), 4 patients achieved complete remission, 3 patients had partial response (PR), 1 with stable disease and 12 had progressed disease.In combined group (n=18), 9 patients achieved complete remission, 2 patients had partial response, 2 with stable disease and 5 had progressed disease.

Results

The majority of patients suffered the following chemo- therapy complications: Nausea, vomiting, pancytopenia and peripheral neuropathy. However, severe chemotherapy-related complications did not occur. The side effects included hot sensations and abdominal discomfort for 8/18 (44%) patients, and no other side effects (burns or blisters) were reported. No late toxicity associated with modulated electro-hyperthermia was observed.

Conclusion

This present study demonstrated the feasibility and advantages of chemotherapy combined with hyperthermia, concurrent with the application of platinum derivatives, for patients with recurrent cervical cancer who have regional lymph node metastasis. The overall response rate for patients treated with chemotherapy combined with modulated electro-hyperthermia was significantly greater than that for those treated with chemotherapy alone.

Article Reference link: click here

Scientific article publishing date : 03/02/2017

Immucura identifier :BSC21_070EN

ALL SCIENTIFIC PAPERS
CONTACT US